Roche seeking earlier use for Lunsumio in FL on Phase III data
Roche is seeking a label expansion to use Lunsumio (mosunetuzumab) at an earlier stage after it showed benefit in a…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail
-
-
Altis Labs’ AI software detected treatment benefit earlier in oncology trial
Altis Labs’ artificial intelligence (AI)-powered imaging endpoint has shown its ability to detect early, notable treatment effects more effectively than…
-
Axoltis’ Phase II ALS trial fails; company points to exploratory endpoints
Axoltis Pharma is undertaking additional analysis of its Phase II amyotrophic lateral sclerosis (ALS) trial after it failed to meet…
-
OCT China 2026: China becoming ‘centre of gravity’ in global clinical trial sector
China’s rapid growth in recent years has sent ripples across the pharmaceutical sector. The country has experienced significant growth over…
-
Trial run: FDA launches pilot for expedited INDs
The US Food and Drug Administration (FDA) is set to launch its expedited investigational new drug (IND) pilot as it…
-
Vera set up for full approval for Trutakna in IgAN with Phase III win
Vera Therapeutics looks well placed for full approval of Trutakna (atacicept-vymj) in primary IgA nephropathy (IgAN) after successful confirmatory data.…
-
CTS China 2026: Building resilience for Chinese biotechs to go global
If Chinese biotechs hope to expand globally, they need to build greater resilience to navigate the differing regulatory and import…
-
J&J’s Rybrevant linked to longest median OS in exon 20 EGFR NSCLC
Johnson & Johnson’s (J&J's) Rybrevant (amivantamab-vmjw) plus chemotherapy has been linked to the longest median overall survival (OS) seen in…
-
A practical framework for choosing e-signatures in global trials
Ask a clinical trial sponsor when to use a qualified e-signature (QES) instead of a standard e-signature (AES), and you'll…
-
Akeso and Summit’s ivonescimab meets OS goals in NSCLC
Akeso and Summit Therapeutics’ ivonescimab has shown further benefit in a first-line non-small cell lung cancer (NSCLC) Phase III study,…